Atlantis Symbicort

NCT00646594 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2009-03-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether Symbicort compared with Advair, will be more effective in controlling asthma in adults and adolescents.

Conditions

Interventions

DRUG

budesonide/formoterol (Symbicort)

DRUG

fluticasone/salmeterol (Advair)

Sponsors & Collaborators

Principal Investigators

  • Mitchell Golmand, MD · AstraZeneca

  • Catherine Bonuccelli · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2005-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646594 on ClinicalTrials.gov